RecruitingPhase 1NCT06672523
A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion
A Phase 1 Study to Evaluate the Mass Balance, Metabolism, Excretion, and Pharmacokinetics of [14C]-BMS-986504 (MRTX1719) in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion
Sponsor
Bristol-Myers Squibb
Enrollment
8 participants
Start Date
Mar 24, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the mass balance, metabolism, elimination, and drug levels of \[14C\]-BMS-986504 (MRTX1719) in participants with advanced solid tumors with homozygous methylthioadenosine phosphorylase deletion.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Participants must have an advanced, unresectable, or metastatic solid tumor malignancy with a deletion of the methylthioadenosine phosphorylase (MTAP) gene.
- Participants must have received, be refractory to, be ineligible for, or be intolerant of available standard care for their cancer.
Exclusion Criteria3
- Participants must not have a history of any surgical or medical conditions possibly affecting how the study drug is distributed, broken down (metabolized) and removed (excreted or eliminated) from the body.
- Participants must not have participated in a clinical study involving a radiolabeled study drug within 12 months prior to admission to the research center.
- Participants must not have a current or recent (within 3 months of study drug administration) gastrointestinal disease.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGBMS-986504
Specified dose on specified days
DRUG[14C]-BMS-986504
Specified dose on specified days
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06672523